NEW YORK - Shares of biotech company Genentech Inc. fell on Tuesday after its experimental drug Avastin failed in a key trial among patients with breast cancer, a major setback for the high-profile medicine, which is also being studied for other types of tumors.... ...
Note: this page has been archived under Muzi Premium Version and is only available to premium members. Please use the Premium Personal Password (PPP) to log in.